Lack Of Incentives Threatens AMR Investment

Over A Third Of AMRIA Members Have Said They Could Cut AMR Spending

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

The AMR Industry Alliance’s 2021 progress report has found that the life sciences industry is helping to shape a positive future outlook in the fight against antimicrobial resistance despite supply-chain disruptions for generics firms, but continued cross-sector collaborations along with policy and regulatory changes toward a more sustainable marketplace are needed.

Antimicrobial susceptibility resistance diffusion test
AMRIA members contributed to R&D on 93 AMR products and technologies • Source: Alamy

Members of the AMR Industry Alliance have continued to engage in antimicrobial resistance research and development, the organization’s annual progress report has found, with 53 of its members together investing $1.8bn to $1.9bn in AMR-relevant R&D in FY2019 and FY2020. However, 32% of members expect to decrease their investment in this space if market conditions do not improve.

AMRIA was established in 2017 and now has 108 members across biopharmaceutical, biotechnology, diagnostic and generics companies as well as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

  • Amneal Kicks Off China Business With First Approval

    Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

  • Nichi-Iko Warns Over Delays From Toyama Plant

    Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.